Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Oncology and MASH Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FASN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FASN Full-Length & Domain Recombinant Protein (Targeted Domains) High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. |
View FASN Products |
| Gene Delivery | FASN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View FASN Products |
| Benchmark Ab | Anti-FASN Monoclonal Antibody (Sequence of Benchmark Antibody) Recombinant positive control for Western / IHC / Screening. |
View FASN Products |
| Validator | FASN siRNA Set For knockdown verification. |
View FASN Products |
| ACLY | ATP Citrate Lyase (ACLY) Synergistic de novo lipogenesis pathway enzyme. |
View ACLY Products |
| ACACA | Acetyl-CoA Carboxylase Alpha (ACACA) Rate-limiting partner in fatty acid synthesis. |
View ACACA Products |
| SCD | Stearoyl-CoA Desaturase (SCD) Downstream desaturase; dual-inhibition rational design target. |
View SCD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse preclinical evaluation | Human / Mouse / Cyno FASN ortholog proteins with >95% purity, Sequence Verified. |
| Off-target liability against lipogenic homologs (ACLY, ACACA, SCD) | Homolog panel proteins strictly verified by mass spec for counter-screening. |
| Preserving domain-specific enzymatic conformation | HEK293 expressed (native glycosylation), High Purity (>95%), Theoretical MW verified. |
| Lack of detection & inhibition controls | Benchmark Anti-FASN Antibodies and catalytic-domain standards included. |
| False positives in cellular lipogenesis assays | Validated FASN siRNA Set for target-specificity checks. |
Live FASN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FASN (Fatty Acid Synthase) therapeutics is intensifying. FASN is the core enzyme of de novo lipogenesis, with proven roles in metabolic diseases (MASH/NASH) and oncology (breast, lung, glioblastoma). Major players are shifting focus from broad applications to targeted small molecule inhibitors and modal combinations. The lead compound, Denifanstat (TVB-2640, Sagimet Biosciences), has advanced to Phase 3 for MASH and Phase 2 for solid tumors. A wave of next-generation molecules includes domain-specific inhibitors, covalent inhibitors (e.g., Ascentage Pharma, Kura Oncology) to overcome acquired resistance, and PROTAC degraders for event-driven pharmacology. Rational combination strategies (anti-PD-1, CDK4/6, EGFR, KRAS inhibitors) are emerging to block metabolic rewiring. On the horizon, siRNA/gene therapy approaches (Alnylam, Arrowhead) target hepatic FASN for metabolic syndrome. The market is projected to grow as MASH combination therapies and tumor metabolism–based precision treatments expand.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Domain-specific) | Sagimet Biosciences, Ascletis Pharma, 3V Biosciences | MASH (NASH), Breast Cancer, NSCLC, Glioblastoma | Selectivity Assay: Need high-purity active full-length FASN & mutant variants. |
| Small Molecule (Covalent) | Ascentage Pharma, Kura Oncology | Glioblastoma, KRAS-mutant NSCLC | Biochemical Kinetics: Need high-purity active enzymes. |
| PROTAC / Degrader | Early-stage biotech / Academia | Solid Tumors | Ternary Complex Formation: Need full-length FASN + E3 ligase platform. |
| siRNA / Gene Therapy | Alnylam, Arrowhead (pathway equivalents); Emerging preclinical | Metabolic Oncology, Metabolic Syndrome | Phenotypic Screening: Need Lentivirus for stable cell lines & siRNA controls. |
Related Targets for Combination Strategies
- View ACLY Products (ATP Citrate Lyase): upstream acetyl-CoA provider. Dual inhibition with FASN is actively explored.
- View ACACA Products (Acetyl-CoA Carboxylase Alpha): rate-limiting step; combined ACC/FASN blockade synergistically reduces lipogenesis.
- View SCD Products (Stearoyl-CoA Desaturase): downstream desaturase essential for membrane fluidity; dual targeting may overcome compensatory desaturation.